|
C14ORF167 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.6242562850266E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.66453525910038E-15 |
| Normal-vs-Stage2 |
1.5603499999961E-05 |
| Normal-vs-Stage3 |
5.44009282066327E-15 |
| Normal-vs-Stage4 |
1.83186799063151E-13 |
| Stage1-vs-Stage2 |
1.611400E-01 |
| Stage1-vs-Stage3 |
4.136500E-02 |
| Stage1-vs-Stage4 |
4.820700E-03 |
| Stage2-vs-Stage3 |
1.051570E-02 |
| Stage2-vs-Stage4 |
3.195400E-03 |
| Stage3-vs-Stage4 |
4.278400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
5.17197396021629E-12 |
| Normal-vs-AfricanAmerican |
1.46459999683657E-08 |
| Normal-vs-Asian |
9.80929999450098E-08 |
| Caucasian-vs-AfricanAmerican |
1.025380E-01 |
| Caucasian-vs-Asian |
1.695380E-01 |
| AfricanAmerican-vs-Asian |
3.088100E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.03312930327593E-13 |
| Normal-vs-Female |
1.6242562850266E-12 |
| Male-vs-Female |
9.626600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.64002145197628E-12 |
| Normal-vs-Age(41-60Yrs) |
1.66533453693773E-14 |
| Normal-vs-Age(61-80Yrs) |
6.39244213118673E-12 |
| Normal-vs-Age(81-100Yrs) |
2.036500E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.812200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.849000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.741200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.860000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.533800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.333000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.789300E-04 |
| Classical-VS-Follicular |
5.598200E-03 |
| Classical-VS-Other |
2.700200E-01 |
| Classical-VS-Normal |
5.31580335305648E-11 |
| Tall-VS-Follicular |
6.90180000040286E-07 |
| Tall-VS-Other |
1.102440E-01 |
| Tall-VS-Normal |
1.64435132177232E-12 |
| Follicular-VS-Other |
9.996800E-01 |
| Follicular-VS-Normal |
2.11510000003301E-06 |
| Other-VS-Normal |
3.974100E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
5.89495119385219E-12 |
| Normal-vs-N1 |
2.34279262656401E-12 |
| N0-vs-N1 |
6.719700E-03 |
|
|
